Jax DiEugenio

Dr Mittendorf on Expanding ASCO’s Mission Through Research Advocacy and Global Collaboration

June 6th 2025

Elizabeth Mittendorf, MD, PhD, MHCM, discusses advancing ASCO’s mission through research advocacy, global collaboration, and a commitment to equity.

Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress

June 6th 2025

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

Generic Eltrombopag Expands Access and Flexibility in ITP and Severe Aplastic Anemia

June 5th 2025

Kanwarpal S. Kahlon, MD, discusses the implications of the availability of generic eltrombopag for immune thrombocytopenia and severe aplastic anemia.

Dr Mittendorf Charts Vision as ASCO President-Elect to Advance Multidisciplinary Care and Research Equity

June 5th 2025

Elizabeth Mittendorf, MD, PhD, shares her ASCO priorities: expanding trial access, strengthening teams, and advancing global, evidence-based oncology care.

Dr Saad on the FDA Approval of Darolutamide in mCSPC

June 4th 2025

Fred Saad, MD, discusses the FDA’s approval of darolutamide without chemotherapy for metastatic castration-sensitive prostate cancer

Annamycin Drives Clinical Benefit in Soft Tissue Sarcoma Lung Metastases

June 4th 2025

Annamycin yielded a 59.4% CBR and a median OS of 13.5 months in soft tissue sarcoma lung metastases.

Iopofosine I 131 Earns FDA Breakthrough Designation for R/R Waldenström Macroglobulinemia

June 4th 2025

The FDA granted breakthrough therapy designation to iopofosine I 131 for relapsed/refractory Waldenström macroglobulinemia.

Accelerated FDA Approval Establishes Role of Avutometinib/Defactinib in KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer

June 4th 2025

The FDA has granted accelerated approval to avutometinib/defactinib for KRAS-mutant recurrent low-grade serous ovarian cancer.

Dr Olawaiye on Data for Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

June 2nd 2025

Alexander Olawaiye, MD, discusses the efficacy and safety of relacorilant plus nab-Paclitaxel in platinum-resistant ovarian cancer.

Dr Duska on the Role of Immunotherapy With Definitive Treatment in High-Risk, Locally Advanced Cervical Cancer

June 2nd 2025

Linda R. Duska, MD, MPH, on incorporating immunotherapy into definitive therapy for high-risk, locally advanced cervical cancer.

Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer

June 2nd 2025

Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.

Dr Char on the Association Between the Empirical Dietary Inflammatory Pattern and Survival Outcomes in Stage III Colon Cancer

June 1st 2025

Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.

Dr Spigel on Adjuvant Chemotherapy in Stage IA/IIA, Molecularly Higher-Risk NSCLC

June 1st 2025

David Spigel, MD, discusses evaluating the utility of adjuvant chemotherapy in patients with stage IA to IIA NSCLC identified as high risk by a 14-gene molecular assay.

Dr Matrana on the Persisting Need For Validated Biomarkers to Guide Treatment Selection in RCC

May 31st 2025

Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.

Dr Picozzi on the Addition of TTFields to Gemcitabine and Nab-Paclitaxel in Locally Advanced PDAC

May 31st 2025

Vincent Picozzi, MD, discusses the addition of TFields to gemcitabine and nab-paclitaxel in locally advanced pancreatic ductal adenocarcinoma.

Dr Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC

May 31st 2025

Raffaele Califano, MD, discusses molecularly stratified outcomes amivantamab with chemotherapy vs chemotherapy alone in patients with advanced EGFR-mutant NSCLC.

Dr Hernandez-Ilizaliturri on the Design of an Observational Study of Immunologic Changes With Venetoclax in CLL

May 31st 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses the design of an observational study investigating immunologic changes with venetoclax in CLL.

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

May 29th 2025

Dr Maroto-Martin on the Mechanism of MZB1-Targeted CAR T-Cell Therapy in Myeloma and Waldenström Macroglobulinemia

May 29th 2025

Elena Maroto-Martin, PhD, discusses the mechanism of action and therapeutic rationale for an MZB1-targeted CAR T-cell therapy in of multiple myeloma and Waldenström macroglobulinemia.

Fixed-Duration Bispecific Antibodies Are Effective, Safe, and Convenient for Follicular Lymphoma

May 29th 2025

Vivek Patel, MD, discusses the safety of bispecific antibodies and the choice between these agents and CAR T-cell therapy for follicular lymphoma.